Literature DB >> 27012367

Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.

Sourav Paul1, Girdhari Lal1.   

Abstract

γδ T cells are an important innate immune component of the tumor microenvironment and are known to affect the immune response in a wide variety of tumors. Unlike αβ T cells, γδ T cells are capable of spontaneous secretion of IL-17A and IFN-γ without undergoing clonal expansion. Although γδ T cells do not require self-MHC-restricted priming, they can distinguish "foreign" or transformed cells from healthy self-cells by using activating and inhibitory killer Ig-like receptors. γδ T cells were used in several clinical trials to treat cancer patient due to their MHC-unrestricted cytotoxicity, ability to distinguish transformed cells from normal cells, the capacity to secrete inflammatory cytokines and also their ability to enhance the generation of antigen-specific CD8(+) and CD4(+) T cell response. In this review, we discuss the effector and regulatory function of γδ T cells in the tumor microenvironment with special emphasis on the potential for their use in adoptive cellular immunotherapy.
© 2016 UICC.

Entities:  

Keywords:  Gamma-delta T cells; inflammation; tolerance; tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27012367     DOI: 10.1002/ijc.30109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling.

Authors:  David T Mulder; Etienne R Mahé; Mark Dowar; Youstina Hanna; Tiantian Li; Linh T Nguyen; Marcus O Butler; Naoto Hirano; Jan Delabie; Pamela S Ohashi; Trevor J Pugh
Journal:  Blood Adv       Date:  2018-12-11

2.  Characterization of γδ T cells in patients with non-small cell lung cancer.

Authors:  Yi Bao; Li Guo; Juanfen Mo
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

3.  γδ T Cell-Based Adoptive Cell Therapies Against Solid Epithelial Tumors.

Authors:  Xiomar Bustos; Sebastian Snedal; Leticia Tordesillas; Eleonora Pelle; Daniel Abate-Daga
Journal:  Cancer J       Date:  2022 Jul-Aug 01       Impact factor: 2.074

4.  Prediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.

Authors:  Xuyong Wei; Wentao Xie; Weiwei Yin; Mengfan Yang; Abdul Rehman Khan; Renyi Su; Wenzhi Shu; Binhua Pan; Guanghan Fan; Kun Wang; Fan Yang; Di Lu; Changbiao Li; Linhui Pan; Beini Cen; Haiyang Xie; Li Zhuang; Shusen Zheng; Xun Zeng; Wei Chen; Xiao Xu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

5.  Immune-mediated syndromes following intravenous bisphosphonate therapy.

Authors:  Noa Markovits; Ronen Loebstein; Ilan Bank
Journal:  Inflammopharmacology       Date:  2017-05-31       Impact factor: 4.473

Review 6.  T cell-mediated immunity to malaria.

Authors:  Noah S Butler; John T Harty; Samarchith P Kurup
Journal:  Nat Rev Immunol       Date:  2019-07       Impact factor: 53.106

7.  Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia.

Authors:  Zhenyi Jin; Qiang Luo; Shuai Lu; Xinyu Wang; Zifan He; Jing Lai; Shaohua Chen; Lijian Yang; Xiuli Wu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2016-11-18       Impact factor: 17.388

Review 8.  Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment.

Authors:  Alessandro Poggi; Massimo Giuliani
Journal:  Vaccines (Basel)       Date:  2016-11-08

Review 9.  Gamma-delta (γδ) T cells: friend or foe in cancer development?

Authors:  Yijing Zhao; Chao Niu; Jiuwei Cui
Journal:  J Transl Med       Date:  2018-01-10       Impact factor: 5.531

10.  HEB is required for the specification of fetal IL-17-producing γδ T cells.

Authors:  Tracy S H In; Ashton Trotman-Grant; Shawn Fahl; Edward L Y Chen; Payam Zarin; Amanda J Moore; David L Wiest; Juan Carlos Zúñiga-Pflücker; Michele K Anderson
Journal:  Nat Commun       Date:  2017-12-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.